SUPPLEMENT SCIENCEInsights
Search

Search Insights

Try choline, nano-curcumin or probiotics.

    Ingredient guide · Ingredient reference

    CoQ10 in diabetes: glucose findings did not mean a better lipid profile

    A small trial reported lower glucose measures without an overall favorable lipid result. Each metabolic endpoint needs its own comparison.

    Read the evidence ↓

    Supplement Science Insights Editorial Team

    Published September 23, 2026 · Updated September 24, 2026

    What the study found

    Fifty people with type 2 diabetes were randomized in a double-blind trial to CoQ10 or maize-starch placebo for twelve weeks; forty completed the trial. The tested preparation supplied 150 mg daily in three 50 mg doses. Participants were younger than 75, had diabetes for at least a year and had HbA1c below 9%; insulin users and people with several major illnesses were excluded. [1][2]

    At twelve weeks, fasting glucose and HbA1c were lower with CoQ10 than with placebo in the reported comparisons adjusted for baseline values. Insulin and HOMA-IR, an insulin-resistance estimate, did not differ significantly between groups. The changes from baseline within the CoQ10 group were not significant for these glycemic measures. [1][2]

    The lipid results were mixed. LDL and total cholesterol were higher with CoQ10 than with placebo at the end of the trial. Triglycerides and HDL did not differ significantly between groups, although both fell within the CoQ10 group while LDL rose. A change within one group does not establish the difference caused by treatment. [1][2]

    What remains unanswered

    Four participants were lost to follow-up and six were excluded for taking less than 70% of the supplements, leaving twenty people in each analyzed group. Excluding one fifth of the randomized sample can affect the result; the report does not establish an intention-to-treat effect for everyone randomized. The small sample, selected population and twelve-week follow-up limit precision and applicability. [2]

    These were blood-test outcomes, not evidence that CoQ10 prevents diabetic complications or replaces diabetes or cholesterol treatment. The paper measured several endpoints and reported statistical significance without confidence intervals for the treatment comparisons. Its findings do not establish the best dose or the clinical importance of the observed differences. [2]

    Funding and conflicts

    The study was supported by the Vice-Chancellor for Research at Iran University of Medical Sciences in Tehran. The authors declared no conflicts of interest. These are the paper’s disclosures; they do not remove the study’s methodological limitations. [2]

    A hypothetical distinction

    Imagine one blood test improves while another worsens. Labeling the entire profile improved would hide information needed to judge the intervention.

    Evidence summary — CoQ10 in diabetes
    DetailInterpretation
    50 randomized40 completed
    Glucose measuresImprovement signal
    Lipid profileNot uniformly favorable
    CoQ10 in diabetes: glucose findings did not mean a better lipid profile — original article outline diagram
    Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

    Sources for this article

    1. Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes: a randomized, double blind, placebo-controlled trial - PubMed
      Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.
    2. Zahedi et al. (2014), Effects of CoQ10 Supplementation on Lipid Profiles and Glycemic Control in Patients with Type 2 Diabetes — full text
      Source consulted: 2026-09-23. This is a reference resource, not a claim that we conducted the studies or tested a product.